Clinical trial NCT01776450: Compassionate Use of the Incraft® AAA Stent Graft System
Official title: Compassionate Use of the Incraft® AAA Stent Graft System
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: Abdominal Aortic Aneurysm
Keywords: Abdominal Aortic Aneurysm
Lead sponsor: Cordis Corporation
Sponsor class: INDUSTRY
First posted: 2013-01-28
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: To treat patients with abdominal aortic aneurysms requiring endovascular repair outside of the clinical protocol through compassionate use.

Detailed description: In the US, abdominal aortic aneurysms (AAA) are found in 4-8% of older men and 0.5-1.5% of older women, resulting in 30,000-40,000 elective procedures and 1,400 peri-operative deaths. The most significant complication of AAA is an aneurysm sac rupture from which more than 15,000 patients die annually and is the 15th leading cause of death in elderly between 60 to 85 years of age . In Japan, it is estimated that approximately 14,000 endovascular aneurysm repair (EVAR) and open surgical repair cases were performed in the year 2010 .

Abdominal aortic aneurysms can be treated three ways: (1) Medical management; (2) Open surgical repair; and (3) Endovascular aneurysm repair (EVAR). EVAR has emerged as an alternative treatment of AAA for most patients. It is less invasive than open repair and carries lower rates of early mortality and morbidity . It has also extended treatment options to patients who cannot undergo conventional surgical procedures due to a high operative risk. As EVAR technology evolves, it allows treatment of AAA with increasing complexity of the aortic neck and access vessels.

The InCraft ®AAA Stent Graft System is designed for endovascular repair of infrarenal AAAs with complex aortic anatomies. This stent-graft system utilizes nitinol stent and polyester graft technology in an ultra-low profile delivery system, which assists the physician in deploying the device in a controlled, consistent, and precise manner within the aortic neck and iliac arteries. By isolating the aneurysmal sac, the system provides an alternative blood flow path to relieve pressure on the arterial vessel walls and minimize aneurysm growth and the potential for aneurysm sac rupture.

Eligibility criteria: 1. Obtain an independent assessment by an uninvolved physician.
2. Obtain informed consent from the patient or legal representative. The consent form used should provide information pertinent to the patient's specific situation. (If appropriate, the study consent form may be used with an addendum to inform the patient of concerns specific to their situation.)
3. Obtain clearance from the institution in accordance with their policies.
4. Notify the institutional review board and comply with their procedures.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Fremont
country: United States
facility: Cordis Corporation
state: California
Study officials:
affiliation: University of Pittsburgh
name: Michel S Makaroun, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Jikei University School of Medicine
name: Takao Ohki, MD
role: PRINCIPAL_INVESTIGATOR
References: